Jane Street Group LLC Acquires Shares of 263,403 Genmab A/S (NASDAQ:GMAB)

Jane Street Group LLC purchased a new stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 263,403 shares of the company's stock, valued at approximately $5,497,000.

A number of other large investors have also added to or reduced their stakes in the company. EverSource Wealth Advisors LLC boosted its position in shares of Genmab A/S by 295.3% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after acquiring an additional 939 shares during the last quarter. Lindbrook Capital LLC raised its stake in Genmab A/S by 105.4% during the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after purchasing an additional 950 shares in the last quarter. GAMMA Investing LLC raised its stake in Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after purchasing an additional 1,051 shares in the last quarter. Barclays PLC lifted its position in Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after purchasing an additional 2,285 shares during the last quarter. Finally, Cromwell Holdings LLC grew its stake in shares of Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock worth $60,000 after buying an additional 2,496 shares in the last quarter. Institutional investors own 7.07% of the company's stock.

Analyst Ratings Changes

GMAB has been the topic of several recent research reports. Sanford C. Bernstein cut shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. Leerink Partners raised Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective on the stock in a research note on Thursday, February 13th. Truist Financial decreased their price objective on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. Leerink Partnrs upgraded Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. Finally, William Blair raised Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $39.17.

Genmab A/S Stock Performance

NASDAQ GMAB traded down $0.23 during trading on Wednesday, hitting $19.08. The stock had a trading volume of 1,705,971 shares, compared to its average volume of 1,104,189. Genmab A/S has a one year low of $17.24 and a one year high of $30.41. The stock has a 50 day simple moving average of $19.90 and a 200 day simple moving average of $20.82. The stock has a market capitalization of $12.23 billion, a price-to-earnings ratio of 10.97, a P/E/G ratio of 2.65 and a beta of 1.04.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.08. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. The firm had revenue of $715.00 million for the quarter, compared to the consensus estimate of $5.17 billion. On average, sell-side analysts predict that Genmab A/S will post 1.45 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.